Table 3 Correlation of clinicopathological features with immunological markers in 83 patients with NPC (including LA-NPC and MET cases)
CD3+ TIL | *P | CD8+ TIL | P | PD-L1 in Tumor Cells | P | ||||
|---|---|---|---|---|---|---|---|---|---|
– | + | – | + | – | + | ||||
Age | |||||||||
< 40 years | 7 (26)♣ | 20 (74) | 0.057 | 5 (19) | 22 (82) | 0.080 | 2 (7) | 25 (93) | 0.002 |
≥ 40 years | 28 (50) | 28 (50) | 22 (39) | 34 (61) | 23 (41) | 33 (59) | |||
WHO Type | |||||||||
I & II | 7 (88) | 1 (12) | 0.009 | 5 (63) | 3 (37) | 0.106 | 5 (63) | 3 (37) | 0.049 |
III | 28 (37) | 47 (63) | 22 (29) | 53 (71) | 20 (27) | 55 (73) | |||
T stage | |||||||||
1&2 | 7 (25) | 21 (75) | 0.036 | 6 (21) | 22 (79) | 0.298 | 5 (18) | 23 (82) | 0.127 |
3 | 8 (40) | 12 (60) | 8 (40) | 12 (60) | 9 (45) | 11 (55) | |||
4 | 20 (57) | 15 (43) | 13 (37) | 22 (63) | 10 (31) | 24 (69) | |||
N stage | |||||||||
0&1 | 7 (50) | 7 (50) | 0.427 | 7 (50) | 7 (50) | 0.060 | 5 (36) | 9 (64) | 0.514 |
2 | 8 (40) | 12 (60) | 9 (45) | 11 (55) | 4 (20) | 16 (80) | |||
3 | 20 (41) | 29 (59) | 11 (22) | 38 (78) | 16 (33) | 33 (67) | |||
M stage | |||||||||
0 | 27 (43) | 36 (57) | 1.000 | 19 (30) | 44 (70) | 0.424 | 18 (29) | 45 (71) | 0.587 |
1 | 8 (40) | 12 (60) | 8 (40) | 12 (60) | 7 (35) | 13 (65) | |||
UICC Stage | |||||||||
III | 5 (36) | 9 (64) | 0.808 | 7 (50) | 7 (50) | 0.142 | 4 (29) | 10 (71) | 0.862 |
IVa | 22 (45) | 27 (55) | 12 (24) | 37 (76) | 14 (29) | 35 (71) | |||
IVb | 8 (40) | 12 (60) | 8 (40) | 12 (60) | 7 (35) | 13 (65) | |||